HEC585

DRUG6 trials

Sponsors

Sunshine Lake Pharma Co., Ltd.

Conditions

Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)

Phase 1

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

CompletedNCT03092102

Sunshine Lake Pharma Co., Ltd.Idiopathic Pulmonary Fibrosis

Start: 2017-05-20End: 2019-02-25Updated: 2020-07-27

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects

CompletedNCT04512170

Sunshine Lake Pharma Co., Ltd.Idiopathic Pulmonary Fibrosis

Start: 2020-07-13End: 2021-08-23Updated: 2022-03-15

To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers

CompletedNCT05383131

Sunshine Lake Pharma Co., Ltd.Idiopathic Pulmonary Fibrosis

Start: 2021-06-23End: 2021-11-30Updated: 2022-05-19

Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects

CompletedNCT07588646

Sunshine Lake Pharma Co., Ltd.Idiopathic Pulmonary Fibrosis

Start: 2021-06-29End: 2021-11-30Updated: 2026-05-15

Phase 2

Phase ll Study of HEC585 in Patients With IPF

Active, not recruitingNCT05060822

Sunshine Lake Pharma Co., Ltd.Idiopathic Pulmonary Fibrosis

Start: 2021-06-30End: 2026-12-11Target: 270Updated: 2026-04-21

Phase 3

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

RecruitingNCT07082842

Sunshine Lake Pharma Co., Ltd.Idiopathic Pulmonary Fibrosis (IPF)

Start: 2025-10-27End: 2032-02-15Target: 472Updated: 2026-04-21